The HOOK2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated gene-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt the function of the HOOK2 gene. This product provides a heterogeneous knockout pool in which the target gene is inactivated across the population, enabling loss-of-function studies without clonal selection. The polyclonal format preserves population-level genetic diversity while ensuring robust abrogation of HOOK2 protein expression, suitable for applications in organelle positioning, intracellular trafficking, and cancer biology.
The parental A-549 cell line was originally established from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits adherent epithelial morphology. These cells are widely employed as an in vitro model for human lung adenocarcinoma, facilitating studies on epithelial barrier function, drug metabolism, and therapeutic efficacy. The well-characterized A-549 background, combined with stable HOOK2 disruption, provides a reliable platform for investigating the molecular underpinnings of lung cancer progression and metastasis.
HOOK2 is a coiled-coil scaffolding protein that links the centrosome and Golgi apparatus to the microtubule network via the dynein-dynactin motor complex, governing organelle positioning. Its activity is regulated by mitotic kinases including CDK1/cyclin B, Aurora A kinase, and PLK1, which phosphorylate HOOK2 to control centrosome dynamics. HOOK2 interacts with PCM1 at centriolar satellites, recruiting components for microtubule anchoring and Golgi stack organization. Downstream, HOOK2 facilitates endocytic trafficking and vesicle transport, critical for cell migration and polarization. Disruption of HOOK2 leads to defective endosomal recycling, impaired Golgi reassembly, and aberrant centrosome duplication, compromising cell division and motility.
In the A-549 adenocarcinoma model, HOOK2 knockout disrupts organelle positioning and intracellular transport, processes often dysregulated in metastatic cells. The loss of function impairs microtubule-dependent trafficking, alters Golgi morphology, and attenuates directional migration??phenotypes linked to tumor invasion. Given the role of A-549 cells in drug metabolism assays, this model may reveal altered chemosensitivity due to defective endocytic recycling. This system provides a robust platform to investigate HOOK2-dependent mechanisms in lung cancer progression and therapy response.
Researchers can employ this polyclonal knockout cell population in a diverse array of experimental approaches, including centrosome and Golgi staining by immunofluorescence, cell migration and invasion assays, endocytosis uptake measurements, and co-immunoprecipitation to map protein-protein interactions. Additional applications encompass cell cycle analysis, proliferation assays, and RT-qPCR or western blotting for verification of target gene disruption. The HOOK2 knockout A-549 cells are well-suited for functional genomic screens, drug sensitivity profiling, and mechanistic studies of microtubule-dependent signaling in cancer. For further technical details and custom inquiries, please contact Ascent Research.
